pharmacy
« Play to win. In presenting his roadmap in early December, Paul Hudson, the new CEO of Sanofi, had warned that it would require a “ reset ”(Reset) of the company. The laboratory unveiled the social aspect on Friday: it will result in 1,700 job cuts in Europe over three years. France is the most affected country with 1,000 jobs concerned (out of 25,000 employees), followed by Germany.
The announcement was made in Paris during a meeting with the European social partners. A meeting with French unions will take place on Monday. “ These are only early retirements and voluntary departures “, Nuances the direction. Tertiary and support functions, as well as R&D are concerned, and in particular “ some sites in Île-de-France », The Paris headquarters, as well as the Val-de-Bièvre campus (Val-de-Marne). No plant closures are planned.
Relocation
Unlike the many social plans announced in recent days, these decisions are not related to the Covid-19. They had also been taken before the health crisis. They come six months after the announcement of the strategic plan of Paul Hudson, in charge since September, responsible for awakening the “ sleeping beauty ” In front of financial analysts, the British boss had announced the end of research in cardiovascular diseases and diabetes. “ Sanofi has not set enough priorities, we must focus on the areas where we can win He said. Namely oncology, rare diseases and vaccines.
To achieve this, the group must become more efficient. The organization has been simplified, grouped around four entities (specialty medicine, vaccines, general medicine and general public health). A savings plan of 2 billion euros was announced in December. It should help increase the operating margin from 27 to 30% by 2022 (and 32% in 2025). “ When such savings are announced, it is rare that there is no impact on employment, comments Jean-Jacques Le Fur, sector specialist at Bryan, Garnier & Co. Especially since at Sanofi, management strata had accumulated in recent years. The company has had a long history of mergers, but without the necessary restructuring that goes hand in hand. »
Unions see these measures as “ continued dismantling of the group and outsourcing of activities ” The Hexagon had already been the subject of 300 job cuts a year ago, linked to a restructuring of R&D and the closure of the Alfortville site. “ France must remain Sanofi’s flagship “Reacted Bercy who asked him to” continue to [y] invest ” The hexagon “ plays a central role in Sanofi’s strategy “Insists a spokesperson, who recalls that an investment of 610 million euros in vaccines was announced a few days ago. Sanofi, which has just created an autonomous entity dedicated to active ingredients, wants to establish itself as a champion in the relocation of pharmaceutical production in France and in Europe.
See also – Are you going to lose your job because of the coronavirus?
– .
